PTHS Channel Pharma: Year-over-year earnings per share growth for the last twelve months

Official company branding of Channel Therapeutics Corp (PTHS)

The prospects for Channel Therapeutics (PTHS) depend on future ion channel tests, with R&D costs already priced in by the market. These expectations are complemented by strict adherence to bioethics and ESG standards in the GURU.Markets terminal, where the quarterly EPS trend has settled at -23.10. The business foundation relies on the development of unique peptide therapies for complex neurological disorders.

Channel Therapeutics Corp (PTHS) Earnings per share growth in annualized terms for the last twelve months: for the period 07/03/2025 - 11/12/2026

Analytical breakdowns for Channel Therapeutics

- share price and consensus valuation forecast:
Stock Quotes Channel Therapeutics Corp|PTHS - Analyst Consensus Forecast
- company stock capitalization data:
Market Value Channel|PTHS - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Channel Therapeutics|PTHS - Total Stockholders' Equity|Market Value to Book Value Ratio channeltherapeutics.com|PTHS - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Channel Therapeutics|PTHS - Long-Term Liabilities to Capital|Short-Term Debt to Capital Channel Therapeutics|PTHS - Company Total Indebtedness|Debt to Book Value Channel|PTHS - Long-Term Debt|Company Short-Term Debts Channel Therapeutics|Quick Ratio channeltherapeutics.com
- earnings and market multiples details:
PTHS - Final Profit|Projected Future Earnings Channel Therapeutics|PTHS - P/E Multiple|Future Price to Earnings Channel|PTHS - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Channel|PTHS - Operating profit before amortization|Net earnings per share (EPS TTM) Channel Therapeutics|PTHS - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months channeltherapeutics.com|PTHS - Earnings per share growth in current year|Expected earnings per share growth for next year Channel Therapeutics
Fundamental company analysis:Channel Therapeutics Corp, PTHS
Manufactured product of Channel Pharma

Channel Therapeutics specializes in developing innovative neurological drugs, where a high burn rate directly impacts final profitability. The quarterly net income per share trend reflects the business's operational efficiency, allowing investors to promptly determine capital momentum and drawdown risks via the quarterly EPS growth trajectory prior to the publication of official reports.

Analysis of competing companies

JAZZ (Jazz Pharmaceuticals plc) - Year-over-year net earnings per share growth for the last 12 months|Cytokinetics Inc. (CYTK) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months PTC Therapeutics Corp|SRRK: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Centessa Pharmaceuticals (CNTA)|DYN - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Edgewise Therapeutics, Inc. EWTX|Rapport Therapeutics Inc - Year-over-year earnings per share growth for the last twelve months|ALMS - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Zevra Corp|CTNM: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year larimartx.com LRMR|Year-over-year net earnings per share growth for the last 12 months CAPR|Earnings per share growth in annualized terms for the last twelve months Entrada Therapeutics Inc. TRDA|Quarterly EPS earnings growth MNOV|Year-over-year net earnings per share growth for the last 12 months Serina Pharma SER|Quarterly EPS earnings growth BTAI (BioXcel Therapeutics)|Year-over-year earnings per one share growth for the last 12 months PMN|Apimeds - Quarterly EPS earnings growth|AEON - Quarterly EPS earnings growth|nlspharma.com (NLSP) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months BNOX|Year-over-year earnings per share growth for the last twelve months FSD Pharma Inc.|Year-over-year earnings per share growth for the last 12 months RETA (reatapharma.com)